BioWorld

Sep. 7, 2005

EpiCept To Take Maxim In $136M Stock Buyout

Privately held pain drug firm EpiCept Corp. entered a deal to pay about $136 million in stock to take over Maxim Pharmaceuticals Inc., and the agreement is expected to close in the fourth quarter. (BioWorld Today) Read More

Cephalon Files For Clearance Of OraVescent Fentanyl Tablet

Chiron Turns Down Novartis' Buyout Offer At $40 Per Share

PDL's Stock Rises On Ularitide Phase II Data, Analyst Upgrade

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 24, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 21, 2026

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

BioWorld

Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...

At AACR: Epigenetic fingerprints in metastases track tumor origin

BioWorld

When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...

Illustration of human face that looks abstract and digital

AACR 2026: The age of agentic AI in oncology

BioWorld Science

New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...